Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Time to Next Treatment (TNT) — 26.7 months

Primary: Response Rate — 0 percentage of patients responding

Primary: Recommended Phase II Dose of the Combination of XL888 and Pembrolizumab as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version…

Primary: Comparison of Progression-free Survival — 6.1; 2.4 Months — p=0.43

Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants

Primary: Complete and Partial Response Rate — 0; 1; 4; 11 participants

Primary: Serious Adverse Events — 0 Participants

Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months

Primary: Part 1: Establish the Maximum Tolerated Dose (MTD) — 100 mg

Primary: Number of Patients With Adverse Events — 5; 0 Participants

Primary: Overall Survival at 6 Months — 36 percentage of participants

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012

Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants

Primary: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) — .38 proportion of patients

Primary: Number of Patients With Each Response in "Good Risk" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression]) — 0…

Primary: Completeness of Cytoreduction

Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months

Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants

Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83

Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants

Primary: Objective Response Rate (ORR) — 3.92 Participants (%)

Primary: Participants Exhibiting Immune Response — 11 Participants

Primary: The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or…

Primary: Progression-Free Survival (PFS) — 9 Participants

Primary: Changes in Combined Positive Scoring (CPS) in Non-irradiated Sites Assessed by Flow Cytometry — 3.9 fold change — p=0.60

Primary: Number of Adverse Events — 250; 119; 24; 0 events

Primary: The Incidence of Dose Limiting Toxicities (DLT) in Phase I Dose Escalation — 0; 0; 1 participants